← Eichor
Study identifier: NCT07493447 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Condition: Meningioma · Glioblastoma · Acoustic Neuroma  ·  Sponsor: Eben Rosenthal

PhaseEARLY_Phase 1
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

This description comes directly from the study's public registry record.

Talk to the study team

Makenna Brown  ·  615-421-4370  ·  makenna.l.brown@vumc.org

Nicole Jones  ·  615-936-2807  ·  nicole.l.jones@vumc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07493447